Company / R&D Expense
Ultragenyx Pharmaceutical Inc. R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$750.0M
FY2025
5-year range
$357.4M / $750.0M
FY2021-FY2025
Trend
+7.4%
vs FY2024
Sector context
#27 of 210
Health Care
What the data says
Ultragenyx Pharmaceutical Inc.'s r&d expense of $750M is higher than 87% of companies in the Health Care sector (FY2025). R&D Expense has fluctuated over the past 10 years, ranging from $46M in FY2016 to $750M in FY2025.
Based on SEC 10-K filings.
$750M in FY2025 with a 5-year CAGR of +20.6%. Top quartile in the Health Care sector.
Improved from $648M to $750M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +2.0%
- 5-Year CAGR
- +20.6%
- 10-Year CAGR
- -
Sector benchmark
+16.4% above sector average
Key checks
Key Insights
- 5-year CAGR of +20.6%, indicating consistent growth.
- In FY2025, r&d expense increased 7.4% year-over-year.
- Ranks #27 out of 210 companies in the Health Care sector.
- Lowest r&d expense in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score -2.91 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $750.0M | +7.4% |
| FY2024 | $698.0M | +7.7% |
| FY2023 | $648.0M | -8.2% |
| FY2022 | $705.8M | +97.5% |
| FY2021 | $357.4M | +21.6% |
| FY2020 | $294.0M | +26.9% |
| FY2019 | $231.6M | -21.2% |
| FY2018 | $294.0M | +156.2% |
| FY2017 | $114.7M | +149.6% |
| FY2016 | $46.0M | -59.9% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026